Injection supplies, shipping, lab work, and clinician fees can add $10 to $100+ per month if not included
The broader pharmaceutical industry is aggressively pursuing differentiated incretin therapies capable of addressing patient tolerability and adherence challenges
One study reported that 43.8% of participants who discontinued treatment did so due to nausea and vomiting, while 36.8% stopped because of gastrointestinal discomfort [14]
Shots: The Weight Loss Data Until recently, the stomach was a dead zone for GLP-1s because stomach acid and digestive enzymes break down peptides before the body can absorb all of them
Pennsylvanias Medicaid coverage of the drugs is expected to cost $1.3 billion in 2025 up from a fraction of that several years ago and is contributing to projections of a multibillion-dollar budget deficit
This combination isn't just about hitting a protein target, it's a scientifically-backed approach to supporting body composition during weight management